Novartis | NVS - Beneficio Bruto En Ventas





Beneficio Bruto En Ventas Cambio Fecha
AbbVie USD 12.54B 474M 2026-03
Amgen USD 6.89B 415M 2025-12
AstraZeneca USD 12.61B 225M 2026-03
Bausch Health Companies USD 2B 67M 2025-12
Biogen USD 1.82B 169.5M 2026-03
Bristol-Myers Squibb USD 8.41B 381M 2025-12
Canopy Growth CAD 8.26M 13.2M 2026-03
Corcept Therapeutics USD 162.02M 37.56M 2026-03
Drreddys Laboratories INR 43.04B 3.77B 2026-03
Eli Lilly USD 15.92B 1.33B 2025-12
Gilead Sciences USD 5.52B 791M 2026-03
GlaxoSmithKline GBP 5.75B 429M 2026-03
Glaxosmithkline GBP 5.75B 2.99B 2026-03
J&J USD 17.24B 642M 2026-03
Merck USD 10.85B 2.57B 2025-12
Novartis USD 10.07B 184M 2026-03
Novartis USD 10.07B 758M 2026-03
Pacira USD 126.64M 15.61M 2026-03
Perrigo USD 325.5M 36.7M 2026-03
Pfizer USD 11.04B 1.24B 2026-03
Phibro Animal Health USD 133.5M 12.6M 2025-12
Prestige Brands USD 157.37M 5.79M 2025-12
Roche Holding CHF 22.09B 10.04B 2025-12
Sanofi EUR 8.45B 1.31B 2025-12
Sanofi EUR 8.11B 343M 2026-03
Supernus Pharmaceuticals USD 129.36M 34.68M 2026-03
Zoetis USD 1.62B 20M 2026-03